Endothelial Derived Hyperpolarization Factor and Vascular Control
Status unconfirmed · Phase 4 · Has a placebo group
Conditions studied: Healthy
In brief
Most cardiometabolic diseases are characterized by increased muscle sympathetic nerve activity (MSNA) during rest and exercise which contributes to poor health outcomes. In healthy humans during muscle contraction, there is a blunting of skeletal muscle vascular responsiveness to increases in MSNA. However, the exact mechanisms involved are unknown although, best evidence suggests that the mechanism is endothelium derived, but nitric oxide (NO) and prostaglandin (PG) independent. Endothelium-derived hyperpolarizing factor (EDHF) is a NO and PG independent vasodilator in both cerebral and skeletal muscle circulations, however, it is unknown if EDHF contributes to vascular responsiveness during elevated MSNA. The application of lower body negative pressure (LBNP) is a safe and non-invasive manipulation that can be used to increase MSNA causing vasoconstriction in humans. Therefore, the purpose of this experiment is to determine if acute inhibition of EDHF alters central and peripheral vascular responses to LBNP at rest and during dynamic exercise. Thereby, providing evidence by which EDHF contributes to vascular control in healthy humans and identify it's potential as a therapeutic target for cardiometabolic diseases that are characterized by elevated MSNA
Key facts
- Study ID
- NCT05176379
- Run by
- University of Oklahoma
- People needed
- 30
- Starts
- 2022-02-19
- Expected to finish
- 2025-05-01
- Last updated by the study team
- 2024-07-23
Who can join
Age: 18 and older, up to 30. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Normotensive (systolic blood pressure < 130 mmHg and/or diastolic blood pressure < 85 mmHg) individuals
- Individuals free of cardiovascular disease and metabolic disease
- Individuals free of any form of autonomic dysfunction
- Individuals with a BMI under 30 kg/m²
- Women that are premenopausal with a regular menstrual cycle (26-30 days)
You may not qualify if…
- Smokers, tobacco users (regular use in the last 6 months)
- Individuals with a blood pressure greater than 130/85
- Subjects who use Amiodarone, Sulphaphenazole
- Subjects who use S-warfarin, Tolbutamine, Phenytoin, Lonafarnib
- Cardiometabolic medication use (e.g. anti-hypertensives, insulin-sensitizing, statins)
- Sex hormone replacement medical use (e.g. testosterone, estrogen, progesterone)
- Pregnancy
Where it is running
- Department of Health and Exercise Science — Norman, Oklahoma, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.